Mirabegron: a novel drug for overactive bladder symptomLI Hai-yuan, ZHOU Feng-hai, MA Yu-lei, L(U) Hai-di2215-2218
Consideration on problems in the pharmacokinetic studies of drugs classified as types 3 or 4 under the new regulations for the registration and managementWEI Min-ji, ZHAO De-heng, ZHAO Ming2219-2223
Discussion and suggestion on the method of histopathologic diagnosis of rat and mouse liver acute injury induced by carbon tetrachlorideJIN Yi, XU Feng, LU Yi2224-2227
Interpreting standardization of clinical trial data from the perspective of drug technical reviewWANG Jun, HAN Jing-jing, HUANG Qin2228-2230,2279
Research progress of matrix metalloproteinase-related anticancer targets and peptide drugsHUA Dan, GONG Min, TANG Li-da2231-2237
Methods and requirements for quality control of recombinant human antithrombus proteinDING You-xue, HAN Chun-mei, LI Xiang, BI Hua, SHI Xin-chang, RAO Chun-ming2238-2241,2245
Determination of valsartan enantiomer in compound valsartan and hydrochlorothiazide tablets by HPLCL(U) Qing, HAO Ling-hua, QI Yan, LI Dong-hui, WU Song2242-2245
Recent advance in research and development of HIV-1 protease inhibitorsYANG Zhi-heng, BAI Xiao-guang, WANG Ju-xian, WANG Yu-cheng2246-2254,2260